Additional file 4: of Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Figure S3. Forest plot: evaluation of the predictive value of clinical factors and biomarkers for the treatment effect in terms of PFS. Biomarkers were categorized as binary variables using the observed median value as the cut-off to illustrate the results. (PPTX 415 kb)